$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

OS Therapies Incorporated (OSTX)OSTX

OS Therapies Incorporated

$1.73

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/20/2024: OSTX (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: 0%	Upturn Advisory Performance 1	Avg. Invested days: 0
Profits based on simulation	Stock Returns Performance 1	Last Close 11/20/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: 0%	Avg. Invested days: 0
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 11/20/2024	Upturn Advisory Performance 1

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 74.14M USD
Price to earnings Ratio -	1Y Target Price 15
Dividends yield (FY) -	Basic EPS (TTM) -0.32
Volume (30-day avg) 22696	Beta -
52 Weeks Range 1.58 - 4.90	Updated Date 11/16/2024

Company Size Small-Cap Stock	Market Capitalization 74.14M USD	Price to earnings Ratio -	1Y Target Price 15
Dividends yield (FY) -	Basic EPS (TTM) -0.32	Volume (30-day avg) 22696	Beta -
52 Weeks Range 1.58 - 4.90	Updated Date 11/16/2024

Earnings Date

Report Date 2024-11-15	When -
Estimate -	Actual -0.1809

Report Date 2024-11-15

When -

Estimate -

Actual -0.1809

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value 90743547	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding 20884600	Shares Floating 16528053
Percent Insiders 24.84	Percent Institutions -

Trailing PE -	Forward PE -	Enterprise Value 90743547	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding 20884600	Shares Floating 16528053
Percent Insiders 24.84	Percent Institutions -

Analyst Ratings

Rating 5	Target Price 15	Buy -
Strong Buy 2	Hold -	Sell -
Strong Sell -

Rating 5	Target Price 15	Buy -	Strong Buy 2
Hold -	Sell -	Strong Sell -

About OS Therapies Incorporated

Exchange	NYSE MKT	Headquaters	Rockville, MD, United States
IPO Launch date	2024-08-01	Founder, Chairman, President & CEO	Mr. Paul A. Romness M.P.H.
Sector	Healthcare	Website	https://ostherapies.com
Industry	Biotechnology	Full time employees	-
Headquaters	Rockville, MD, United States
Founder, Chairman, President & CEO	Mr. Paul A. Romness M.P.H.
Website	https://ostherapies.com
Website	https://ostherapies.com
Full time employees	-

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.